The main limitations of our study were that it was retrospective and involved heterogeneous sites.
The most important findings of our study were that VPA administration produced a progressive and strong increase in the central concentrations of KYNA, KYN and TRP.
The limitations of our study were that being a retrospective study, we had to exclude patients without comparable radiographs for measurements and that we did not investigate into the functional outcome in these patients.
Limitations of our study were that the treatment assignment of DrotAA was not blinded nor randomized, outcomes were obtained retrospectively from databases, and we could not assess safety due to lack of adequate data.
The major findings of our study were that in Phe-induced vasoconstriction, SHR-BB aortas relaxed to a greater degree in comparison to controls when mefenamic acid (MFA) was present and that the incubation with this COX inhibitor failed to restore — and in fact decreased — the maximum vasodilator response to Ach, in comparison to controls.
The important findings in our study were that active immunization results in production of activating antibodies to the α1A-AR, namely α1A-AR-AB.
The main results of our study were that inhibitory cells did respond to MD, but the neuronal subpopulation expressing PV was refractory to MD maintaining normal levels of c-Fos induction by stimulation of the deprived eye.
The major findings of our study were that SNP TLR5_C1174T was associated with increased susceptibility to RUTI, SNP TLR4_A896G was associated with protection from RUTI, and SNP TLR1_G1805T was associated with protection from pyelonephritis.
[ 4] The strengths of our study were that comprehensive measures of potential confounders were available for the entire cohort.
Limitations of our study were that it was a retrospective study with limited number of patients in each group.
The main strengths of our study were that it was prospective, population-based and included data on a range of putative confounders including lifestyle factors and co-morbidities.
